Xencor, Inc.
Records under this name other than the patents Xencor, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 147 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,752,678 | Complement Component C5 Antibodies Formerly held In force · High confidence | In force | High confidence | |
| US 9,701,743 | Complement Component C5 Antibodies Formerly held In force · High confidence | In force | High confidence | |
| US 12,365,743 | ANTI-CD28 X Anti-Psma Antibodies Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 12,378,326 | ANTI-CD28 X Anti-Psma Antibodies Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,574,006 | Optimized Anti-CD30 Antibodies Term ended Ended no later than Oct 6, 2026 · Low confidence | Term ended | Ended no later than Oct 6, 2026 | Low confidence |
| US 9,102,739 | Anti-Glypican-3 Antibody Formerly held Term ended Term ended Oct 4, 2026 · High confidence | Term ended | Term ended Oct 4, 2026 | High confidence |
| US 10,118,959 | Anti-Glypican-3 Antibody Formerly held Term ended Term ended Oct 4, 2026 · High confidence | Term ended | Term ended Oct 4, 2026 | High confidence |
| US 8,883,973 | Fc variants with altered binding to FcRn Term ended Term ended Aug 14, 2026 · From the USPTO record | Term ended | Term ended Aug 14, 2026 | From the USPTO record |
| US 7,557,190 | Optimized proteins that target Ep-CAM Term ended Term ended Jul 18, 2026 · From the USPTO record | Term ended | Term ended Jul 18, 2026 | From the USPTO record |
| US 8,852,586 | Fc Variants with altered binding to FcRn Term ended Term ended Jul 16, 2026 · High confidence | Term ended | Term ended Jul 16, 2026 | High confidence |